All In Biotech

Drug Trial Radar · NCT00101751

INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study

Efficacy and Safety of a Standard Titration Algorithm Coupled With a Conventional Dietary Intervention or Intensive Dietary Intervention Versus a Standard Titration Algorithm, Alone, in Patients With Type 2 Diabetes Initiating NovoLog® Mix 70/30 Therapy

Last checked: Nov 19, 2026Latest source record: Nov 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 4,877 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,877

Actual

Start

Oct 2004

Primary completion

Jun 2006

Study completion Jun 2006

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in the United States of America (USA). The purpose of this study is to compare the effectiveness and safety of a biphasic insulin aspart standard titration regimen when coupled with dietary intervention to standard titration without dietary intervention.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • biphasic insulin aspartDrug

  • dietary regimenBehavioral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c and Incidence of hypoglycemiaTime frame: After 24 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novo Nordisk Clinical Trial Call Center

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.